Evaluation of Laboratory Methods for Detecting Auto Antibodies to Complement Proteins

Overview

About this study

The goal of this study is to validate testing to be performed in the clinical immunology lab and have a source of positive patient sera.

These tests include:

Auto antibodies to Factor H
C3 Nephritic Factor
Auto antibodies to C1q
Auto antibodies to C1INH

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients (6 months old and older) who are suspected to have defects in there complement components.
- This includes patients who are suspected to have atypical HUS, Dense Deposit Disease (DDD) and C3 related glomerulonephritis.

Exclusion Criteria:

Less than 6 months old

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator David Murray, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

David Murray, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials